Shares of Halozyme Therapeutics, Inc. (NASDQ: HALO) below -0.46% and ended at $19.52. The stock’s market capitalization arrived at $2.79B and total traded volume was 520,066 shares. The stock has a 52-week highest price of $21.48 and its 52-week lowest price was called at $11.41. During last trade, its maximum trading price was registered $19.80 and it’s the minimum trading price was noted $19.31.

Halozyme Therapeutics, Inc. (HALO) recently stated financial results and recent highlights for the fourth quarter and full-year ended December 31, 2017.

“Building on a truly transformative year in 2017, we start 2018 executing against a strong portfolio of new ENHANZE collaborations,” stated Dr. Helen Torley, president and chief executive officer. “With Janssen now studying Darzalex® SC in four Phase 3 trials, Roche recently initiating a Phase 1 study with ENHANZE and multiple targets projected to enter the clinic in the coming quarters, we have good line of sight to our goal of having six targets in clinical development by year-end, doubling the number of targets in the clinic from 2017.

Fourth Quarter 2017 and Recent Highlights include:

• Janssen expanding its development program for the subcutaneous formulation of DARZALEX (daratumumab)with six planned and ongoing clinical studies. Halozyme’s ENHANZE technology has the potential to enable a 15-ml injection to be delivered in five minutes or less. The ongoing or planned trials in patients with Amyloidosis, Smoldering Myeloma and Multiple Myeloma include four Phase 3 studies, one Phase 2 study and one Phase 1 study.

Halozyme Therapeutics, Inc.’s (HALO) price volatility for a month noted as 3.56% however its price volatility for a week documented as 2.68%. The corporation holds 147.90 million outstanding shares and its 124.72 million shares were floated in the market. The stock established a negative trend of -1.46% in last week and indicated fall of -6.51% in previous month.

Fourth Quarter 2017 Financial Highlights

• Revenue for the fourth quarter was $189.6Mcontrast to $39M for the fourth quarter of 2016. The year-over-year raise was driven by $101.4M recognized upon the effective date of the BMS collaboration, a $15M milestone payment from Janssen, a $40M upfront payment from Alexion and growth in royalties from partner sales of Herceptin^® (trastuzumab) SC, MabThera^® (rituximab) SC and HYQVIA^® (Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase), offset by a decrease in research and development reimbursements. Revenue for the fourth quarter included $17.7M in royalties, an raise of 24 percent from the prior-year period, $8.4M in sales of bulk rHuPH20 primarily for use in manufacturing alliance products and $4.2M in HYLENEX^® recombinant (hyaluronidase human injection) product sales.

• Revenue for the full year was $316.6M, contrast to $146.7M in 2016.
• Research and development expenses for the fourth quarter were $41.4M, contrast to $41.3M for the fourth quarter of 2016.

  Research and development expenses for the full year were $150.6M, contrast to $150.8M in 2016.

• Selling, general and administrative expenses for the fourth quarter were $14.8M, contrast to $12.2M for the fourth quarter of 2016. The raise was primarily Because of personnel expenses, including stock compensation, for the period.

  Selling, general and administrative expenses for 2017 were $53.8M, contrast to $45.9M in 2016.

• Net income for the fourth quarter was $123.9M, or $0.85 per share, contrast to net loss in the fourth quarter of 2016 of $27.4M, or $0.21 per share.

  Net income for the full year was $63M, or $0.45 per share, contrast to a net loss of $103M in 2016, or $0.81 per share.

• Cash, cash equivalents and marketable securities were $469.2M at December 31, 2017, contrast to $316.9M at September 30, 2017.

In the liquidity ratio analysis; HALO debt to equity ratio was 0.97 while current ratio was 3.90. The company has the institutional ownership of 89.50% while the Beta factor was 1.87. The stock’s RSI amounts to 51.53.